Source: BioPharma-Reporter

VGXI: DNA plasmid manufacturer taking orders for mid-2022 production slots at new site

VGXI, Inc, a provider of plasmid DNA manufacturing and development services, says multiple construction milestones have been reached for its new headquarters and manufacturing facility in Texas.

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Young K Park's photo - President & CEO of VGXI

President & CEO

Young K Park

CEO Approval Rating

- -/100

Read more